[go: up one dir, main page]

AU2001278555A1 - Method for screening peptides for use in immunotherapy - Google Patents

Method for screening peptides for use in immunotherapy

Info

Publication number
AU2001278555A1
AU2001278555A1 AU2001278555A AU7855501A AU2001278555A1 AU 2001278555 A1 AU2001278555 A1 AU 2001278555A1 AU 2001278555 A AU2001278555 A AU 2001278555A AU 7855501 A AU7855501 A AU 7855501A AU 2001278555 A1 AU2001278555 A1 AU 2001278555A1
Authority
AU
Australia
Prior art keywords
iia
class
identifying
peptide
subdominant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278555A
Inventor
David Alexandre Gross
Kostas Kosmatopoulos
Antonio Scardino
Sophie Tourdot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Gustave Roussy (IGR)
Publication of AU2001278555A1 publication Critical patent/AU2001278555A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)

Abstract

Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).
AU2001278555A 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy Abandoned AU2001278555A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0009591A FR2812087B1 (en) 2000-07-21 2000-07-21 METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY
FR00/09591 2000-07-21
PCT/FR2001/002387 WO2002008716A2 (en) 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy

Publications (1)

Publication Number Publication Date
AU2001278555A1 true AU2001278555A1 (en) 2002-02-05

Family

ID=8852782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278555A Abandoned AU2001278555A1 (en) 2000-07-21 2001-07-20 Method for screening peptides for use in immunotherapy

Country Status (11)

Country Link
US (2) US7425606B2 (en)
EP (1) EP1309860B1 (en)
AT (1) ATE378590T1 (en)
AU (1) AU2001278555A1 (en)
CA (1) CA2416761C (en)
DE (1) DE60131413T2 (en)
DK (1) DK1309860T3 (en)
ES (1) ES2296778T3 (en)
FR (1) FR2812087B1 (en)
PT (1) PT1309860E (en)
WO (1) WO2002008716A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
MXPA02007478A (en) 2000-02-04 2004-08-23 Univ Duke Human immunodeficiency virus vaccine.
US7388071B2 (en) * 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
FR2812087B1 (en) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY
EP1752160A3 (en) * 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CA2606871C (en) * 2005-05-09 2014-06-03 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
ES2330658T3 (en) * 2005-12-23 2009-12-14 Vaxon Biotech IMMUNOGEN POLYPEPTIDE COMPOSED BY OPTIMIZED CRYTIC PEPTIDES DERIVED FROM TUMOR ANTIGENS, AND ITS USES.
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
AU2012258603A1 (en) * 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
WO2021133742A1 (en) * 2019-12-23 2021-07-01 The Regents Of The University Of California Stabilization of mhc complexes
CN116710115A (en) 2020-11-20 2023-09-05 思维疗法股份有限公司 Compositions and methods for optimized peptide vaccines
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
DE69435292D1 (en) * 1993-03-05 2010-06-17 Epimmune Inc METHOD FOR THE PRODUCTION OF IMMUNOGENOUS HLA-A2.1-BINDING PEPTIDES
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1995027901A1 (en) * 1994-04-11 1995-10-19 Ixsys, Inc. Class i peptide binding motifs
DE69739062D1 (en) * 1996-03-21 2008-12-04 Circassia Ltd Use of cryptic peptides to induce immunological tolerance
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1126872B1 (en) * 1998-10-29 2006-12-13 Dana-Farber Cancer Institute, Inc. CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
US7388071B2 (en) * 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
FR2812087B1 (en) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY

Also Published As

Publication number Publication date
US20090269363A1 (en) 2009-10-29
FR2812087B1 (en) 2007-05-11
ATE378590T1 (en) 2007-11-15
EP1309860B1 (en) 2007-11-14
CA2416761A1 (en) 2002-01-31
DE60131413D1 (en) 2007-12-27
CA2416761C (en) 2013-04-23
US7976843B2 (en) 2011-07-12
DK1309860T3 (en) 2008-03-17
US7425606B2 (en) 2008-09-16
DE60131413T2 (en) 2008-09-04
US20040072240A1 (en) 2004-04-15
WO2002008716A3 (en) 2003-02-27
FR2812087A1 (en) 2002-01-25
PT1309860E (en) 2008-02-25
ES2296778T3 (en) 2008-05-01
EP1309860A2 (en) 2003-05-14
WO2002008716A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
AU2001278555A1 (en) Method for screening peptides for use in immunotherapy
ATE468127T1 (en) II-KEY/ANTIGENIC EPITOP HYBRID PEPTIDE VACCINE
Antoniades et al. Human platelet-derived growth factor (PDGF): amino-terminal amino acid sequence
Sheldon et al. Loligomers: design of de novo peptide-based intracellular vehicles.
Fischer Lindahl et al. H2-M3, a full-service class Ib histocompatibility antigen
Hurt et al. A cytosolic protein contains a cryptic mitochondrial targeting signal
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
EP0997477A3 (en) MHC complexes and uses thereof
BR9406652A (en) Composition
WO2006076410A3 (en) Li-key/antigenic epitope hybrid peptide vaccines
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
BR9813416A (en) Compositions and methods of recombinant nodaviruses
CA2420350A1 (en) Membrane penetrating peptides and uses thereof
NO995002D0 (en) Modified TNF <alpha> molecules, DNA encoding such modified TNF <alpha> molecules and vaccines comprising such TNF <alpha> molecules and DNA
Bownds et al. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2. 1 binding affinity and stability in solution
WO1999050424A3 (en) Fusion protein comprising a sequence from a major coat protein of a papovavirus
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
CA2819978A1 (en) Immune restricted peptides with increased efficacy
EP2649091A1 (en) Immune restricted peptides with increased efficacy
WO2023038961A3 (en) Common cold coronavirus t cell epitopes, methods and uses thereof
CA2542104A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
AP2368A (en) Novel expression vectors and uses thereof.
Stewart et al. Protein NH2-terminal asparagine deamidase. Isolation and characterization of a new enzyme.
Bauer et al. Proteins of the tight junction in the blood-brain barrier
Rhodes et al. Isolation and characterization of the cyanogen bromide peptides derived from the human. alpha. 2 (V) collagen chain